Bloomage Biotech(SH:688363) Da Zhong Ri Bao·2025-10-26 03:17Core Insights - The article discusses how Huaxi Biotechnology, a leading hyaluronic acid company, is overcoming the "valley of death" in the biotechnology sector through strategic investments and innovations [1][3] Group 1: Strategic Decisions - Huaxi invested 3 billion yuan to build the world's largest pilot testing platform, which is a critical strategic decision for the company [3] - This pilot platform serves as a "translator" and "accelerator" that connects scientific research with industrial application, allowing for the verification of new processes and materials at a lower cost and risk [3] Group 2: Business Model and Synergy - The platform creates strong strategic synergy between Huaxi's B-end raw material business and C-end brand business, enabling continuous exploration of cutting-edge technology and direct capture of consumer demand [3] - The pilot platform acts as a hub that facilitates the rapid transformation of advanced technologies into marketable products, while also allowing market feedback to drive research and development [3] Group 3: Competitive Advantage - This strategic move lays a solid foundation for Huaxi's transformation from a leading hyaluronic acid company to a biotechnology platform enterprise, ensuring a continuous flow of technological reserves to the market [3] - The company is positioned to maintain dynamic competitiveness through ongoing innovation and leadership in the industry [3]